Industry BlueBook

Pharma Services: Development

November 2020

The industry's authoritative information resource for valuations, M&A transactions, and Financings


DASHBOARD^{1,2,3,4,5}

| EV MULTIPLES | | | | | | | | | |
|---------------------------------------|-------|----|---------|----|---|-------|-----|--------|-----|
| | | | REVENUE | | | | | EBITDA | |
| | LTM | %∆ | FTM | %∆ | _ | LTM | %∆ | FTM | %∆ |
| Development Technology & Info Systems | 17.7x | 3% | 14.8x | 3% | | 22.4x | 7% | 42.0x | 3% |
| Development Clinical Services | 3.2x | 8% | 3.2x | 7% | | 18.0x | 8% | 16.4x | 7% |
| Development Laboratory Services | 4.9x | 9% | 4.4x | 3% | | 21.5x | 14% | 20.8x | 17% |


| M&A DEALS & FINANCINGS | | | | | | | | | |
|---------------------------------------|-----|------|------------|------|---|-----|----|--------------|------|
| | | С | EAL COUNT | | | | VC | DLUME (\$MM) | |
| | M&A | %∆ | FINANCINGS | %∆ | _ | M&A | %Δ | FINANCINGS | %∆ |
| Development Technology & Info Systems | 2 | 0% | 3 | -25% | | 0 | NM | 8 | -88% |
| Development Clinical Services | 4 | 100% | 3 | 50% | | 0 | | 22 | 48% |
| Development Laboratory Services | 1 | -50% | 2 | 100% | | 0 | NM | 19 | NM |

- 1. Enterprise value (EV) equals equity market value (market capitalization) plus debt, plus preferred stock, minus cash and cash equivalents
- 2. Deals counted once in total if included in multiple segments
- 3. LTM = last twelve months; FTM = forward twelve months
- 4. $\%\Delta$ percent change month over month
- 5. NM Not Meaningful


12 Month Deal Count M&A




12 Month Volume M&A (\$MM)



12 Month Deal Count Financings



12 Month Volume Financings (\$MM)



M&A ACTIVITY

DEALS BY SEGMENT

Development

| | | evelopment | |
|------------------|------------|--------------------------------------|--------------------|
| Clinical Service | | Dev Tech | Lab Services |
| Trial Execution | Regulatory | Operations Technology | Bioanalytical Labs |
| Clinical Support | Services | Regulatory & Safety Trial Technology | |

U.S. DEALS BY STATE



WORLDWIDE DEALS BY COUNTRY



| SELECTED | SELECTED TRANSACTIONS | | | | | | | | |
|----------------|-----------------------|---|-------------------------|----------------|------------------------|-------------|--|--|--|
| Announced Date | Segment | Sub-Segment | Target Company | Geography | Selected Buyers | Size (\$mm) | | | |
| 11/30/2020 | Dev Tech | Operations Tech Regulatory & Safety Tech | VirTrial, LLC | United States | Signant Health | - | | | |
| 11/23/2020 | Dev Tech | Operations Tech Regulatory & Safety Tech | Longboat | Ireland | Advarra | - | | | |
| 11/23/2020 | Lab Services | Bioanalytical | Fidelta d.o.o. | Croatia | Selvita S.A. (WSE:SLV) | - | | | |
| 11/20/2020 | Clinical Service | Regulatory Services | Certus PV Services Inc. | Canada | Veristat, Inc. | - | | | |
| 11/11/2020 | Clinical Service | Trial Execution | eStudySite, Inc. | United States | VCR Holdings, LLC | - | | | |
| 11/6/2020 | Clinical Service | Trial Execution | Nucleus Global Limited | United Kingdom | Huntsworth plc | - | | | |
| 11/2/2020 | Clinical Service | Clinical Support | IntegReview IRB | United States | Advarra | - | | | |


FINANCINGS

DEALS BY SEGMENT

Development

| | | Development | | | |
|---------------------|---------------|-------------|--------------|--|--|
| Clinical Service | | Dev | Tech | | |
| Trial Execution | Data Services | | Technology | | |
| Regulatory Services | | In Vivo | Central Labs | | |

U.S. DEALS BY STATE



WORLDWIDE DEALS BY COUNTRY



| SELEC | TED TRAN | SACTIONS | | | | |
|-------------|----------------------------------|---|--|----------------|--|-------------|
| Closed Date | Segment | Sub-Segment | Target Company | Geography | Selected Investors | Size (\$mm) |
| 11/19/2020 | Lab Services | In Vivo | DefiniGEN Limited | United Kingdom | Oxford Spin-out Equity Management, 24Haymarket Limited | 4.3 |
| 11/18/2020 | Dev Tech Clinical Service | Operations Tech Trial Execution | Outcomes4me Inc. | United States | Asset Management Ventures, Sierra Ventures | 4.7 |
| 11/3/2020 | Clinical Service Lab Services | Regulatory Services Data Services Central | Shanghai Youlin Pharmaceutical Technology Co., Ltd. | China | Cenova Ventures, Shenzhen Zhenji Capital Private Equity Investment Management Co., Ltd., Shanghai Daohe Long-term Investment Management Co. Ltd. | 14.9 |
| 11/3/2020 | Dev Tech Clinical Service | Operations Tech Trial Execution | Massive Bio, Inc. | United States | Revo Capital, Cavendish Impact Foundation | 2.6 |

| Closed Date Segment | Sub-Segment | Target Company | Geography | Selected Investors | Size (\$mm) |
|---------------------|-----------------|---------------------|----------------|---|-------------|
| 11/2/2020 Dev Tech | Operations Tech | eLucid mHealth Ltd. | United Kingdom | Maven Capital Partners UK LLP, Shallcross Partners Limited | 0.7 |

PUBLIC MARKETS¹

| DEVELOPMENT 1 | DEVELOPMENT TECHNOLOGY & INFO SYSTEMS | | | | | | | | | |
|---------------------|---------------------------------------|------------------|--------|--------|--------|--------|--|--|--|--|
| Company Name | Geography | Enterprise Value | xRever | iue | xEBITE |)A | | | | |
| Company Name | Geography | (\$mm) | LTM EV | FTM EV | LTM EV | FTM EV | | | | |
| IQVIA Holdings Inc. | United States | 44,178 | 4.0x | 3.6x | 22.4x | 16.4x | | | | |
| Veeva Systems Inc. | United States | 40,321 | 31.4x | 26.0x | NM | 67.5x | | | | |
| Mean | | 42,250 | 17.7x | 14.8x | 22.4x | 42.0x | | | | |
| Median | | 42,250 | 17.7x | 14.8x | 22.4x | 42.0x | | | | |

| DEVELOPMENT CLINICAL SERVICES | | | | | | | | |
|--|---------------|------------------|--------|--------|--------|--------|--|--|
| Company Name | Geography | Enterprise Value | xReve | nue | xEBIT | DA | | |
| Company Name | Geography | (\$mm) | LTM EV | FTM EV | LTM EV | FTM EV | | |
| Charles River Laboratories International, Inc. | United States | 13,638 | 4.8x | 4.4x | 18.4x | 17.9x | | |
| CMIC HOLDINGS Co., Ltd. | Japan | 459 | 0.6x | 0.6x | 6.2x | 6.6x | | |
| ICON Public Limited Company | Ireland | 10,012 | 3.6x | 3.2x | 20.0x | 18.6x | | |
| IQVIA Holdings Inc. | United States | 44,178 | 4.0x | 3.6x | 22.4x | 16.4x | | |
| Linical Co., Ltd. | Japan | 155 | 1.5x | 1.5x | 14.5x | 12.7x | | |
| Medpace Holdings, Inc. | United States | 4,473 | 5.0x | 4.2x | 23.6x | 20.6x | | |
| PPD, Inc. | United States | 16,055 | 3.7x | 3.2x | 20.2x | 16.8x | | |
| PRA Health Sciences, Inc. | United States | 8,344 | 2.7x | 2.5x | 17.7x | 14.5x | | |
| Seiko Epson Corporation | Japan | 5,374 | 0.6x | 0.6x | 6.3x | 5.3x | | |
| Shin Nippon Biomedical Laboratories, Ltd. | Japan | 359 | 2.5x | NM | 8.1x | NM | | |
| Syneos Health, Inc. | United States | 9,444 | 2.1x | 1.9x | 14.3x | 13.3x | | |
| WuXi AppTec Co., Ltd. | China | 36,370 | 15.5x | 12.0x | 67.3x | 45.1x | | |
| Mean | | 12,405 | 3.9x | 3.4x | 19.9x | 17.1x | | |
| Median | | 8,894 | 3.2x | 3.2x | 18.0x | 16.4x | | |

| DEVELOPMENT LABORATORY SERVICES | | | | | | | | | |
|--|---------------------|------------------|--------|--------|---------|--------|--|--|--|
| Company Name | Geography | Enterprise Value | xReve | nue | xEBITDA | | | | |
| Company Name | Geography | (\$mm) | LTM EV | FTM EV | LTM EV | FTM EV | | | |
| Champions Oncology, Inc. | United States | 144 | 4.1x | 3.6x | NM | 79.9x | | | |
| Charles River Laboratories International, Inc. | United States | 13,638 | 4.8x | 4.4x | 18.4x | 17.9x | | | |
| Eurofins Scientific SE | Luxembourg | 18,661 | 3.3x | 2.9x | 15.8x | 12.5x | | | |
| Evotec SE | Germany | 5,231 | 9.0x | 8.3x | 47.6x | 35.3x | | | |
| Frontage Holdings Corporation | United States | 791 | 7.8x | 5.9x | 47.4x | 22.8x | | | |
| ICON Public Limited Company | Ireland | 10,012 | 3.6x | 3.2x | 20.0x | 18.6x | | | |
| Joinn Laboratories (China) Co., Ltd. | China | 3,091 | 22.0x | 19.8x | 78.5x | 69.4x | | | |
| KNOTUS Co.,Ltd | Korea (Republic of) | 152 | 3.1x | NM | 17.4x | NM | | | |
| Medpace Holdings, Inc. | United States | 4,473 | 5.0x | 4.2x | 23.6x | 20.6x | | | |
| Personalis, Inc. | United States | 877 | 11.4x | 10.6x | NM | NM | | | |
| Pharmaron Beijing Co., Ltd. (SZSE:300759) | China | 10,510 | 14.7x | 11.4x | 51.9x | 43.2x | | | |

| PPD, Inc. | United States | 16,055 | 3.7x | 3.2x | 20.2x | 16.8x |
|---|---------------|--------|-------|-------|-------|-------|
| PRA Health Sciences, Inc. | United States | 8,344 | 2.7x | 2.5x | 17.7x | 14.5x |
| Selvita S.A. | Poland | 210 | 5.0x | 5.4x | 22.8x | 21.0x |
| Shanghai Medicilon Inc. | China | 1,205 | 13.9x | NM | 73.8x | NM |
| Shin Nippon Biomedical Laboratories, Ltd. | Japan | 359 | 2.5x | NM | 8.1x | NM |
| Syneos Health, Inc. | United States | 9,444 | 2.1x | 1.9x | 14.3x | 13.3x |
| WuXi AppTec Co., Ltd. | China | 36,370 | 15.5x | 12.0x | 67.3x | 45.1x |
| Mean | | 7,754 | 7.5x | 6.6x | 34.0x | 30.8x |
| Median | | 4,852 | 4.9x | 4.4x | 21.5x | 20.8x |
| | | | | | | |

RECENT CROSSTREE TRANSACTIONS

Crosstree Capital Partners provides mergers and acquisitions and financing advisory services exclusively to leading Health Sciences companies. Since inception, the firm has been a consistent leader within our focus areas, closing more than 100 successful transactions with companies ranging from private equity-backed consolidators to Fortune 500 publicly-traded companies. In the process, we have represented clients on five continents, and roughly 35% of our transactions have been cross-border.

















Contact Us

Shane Senior, CFA
Head of Pharma Services
813-774-4755
shane.senior@crosstreecapital.com
www.crosstreecapital.com

Locations

Tampa (Headquarters) 2701 North Rocky Point Dr Tampa, FL 33607 New York 420 Lexington Ave New York, NY 10170